Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)
- 15 May 2011
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (10), 3152-3158
- https://doi.org/10.1016/j.bmcl.2011.02.114
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingCell Chemical Biology, 2011
- Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsCancer Biology & Therapy, 2009
- Mirk Regulates the Exit of Colon Cancer Cells from QuiescencePublished by Elsevier BV ,2009
- The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation siteBMC Biochemistry, 2006
- Mirk/Dyrk1B: A Multifunctional Dual-Specificity Kinase Involved in Growth Arrest, Differentiation, and Cell SurvivalCell Biochemistry and Biophysics, 2006
- Manipulation of Alternative Splicing by a Newly Developed Inhibitor of ClksPublished by Elsevier BV ,2004
- Pre-mRNA splicing and human diseaseGenes & Development, 2003
- Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing FactorsMolecular and Cellular Neuroscience, 2001
- Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells.2000
- Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein KinasesPublished by Elsevier BV ,1998